EP3129469A1 - Cell-surface marker of early msc aging - Google Patents
Cell-surface marker of early msc agingInfo
- Publication number
- EP3129469A1 EP3129469A1 EP15776062.0A EP15776062A EP3129469A1 EP 3129469 A1 EP3129469 A1 EP 3129469A1 EP 15776062 A EP15776062 A EP 15776062A EP 3129469 A1 EP3129469 A1 EP 3129469A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mscs
- stem cells
- mesenchymal stem
- cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000032683 aging Effects 0.000 title claims abstract description 48
- 239000002458 cell surface marker Substances 0.000 title claims abstract description 22
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 claims abstract description 191
- JUHWMDGJJNVWIZ-UHFFFAOYSA-N 4-chloro-n-(2-piperidin-1-ylethyl)-2-prop-2-enoxybenzamide Chemical compound C=CCOC1=CC(Cl)=CC=C1C(=O)NCCN1CCCCC1 JUHWMDGJJNVWIZ-UHFFFAOYSA-N 0.000 claims abstract description 186
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 claims abstract description 186
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims abstract description 60
- 230000035755 proliferation Effects 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 31
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 216
- 230000014509 gene expression Effects 0.000 claims description 54
- 230000001332 colony forming effect Effects 0.000 claims description 16
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 9
- 230000033558 biomineral tissue development Effects 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 4
- 238000012216 screening Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 113
- 239000003550 marker Substances 0.000 description 22
- 230000009758 senescence Effects 0.000 description 21
- 102000005936 beta-Galactosidase Human genes 0.000 description 19
- 108010005774 beta-Galactosidase Proteins 0.000 description 19
- 102000009058 Death Domain Receptors Human genes 0.000 description 18
- 108010049207 Death Domain Receptors Proteins 0.000 description 18
- 230000004069 differentiation Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 230000003716 rejuvenation Effects 0.000 description 14
- 108700012411 TNFSF10 Proteins 0.000 description 12
- 230000001172 regenerating effect Effects 0.000 description 12
- 238000010186 staining Methods 0.000 description 11
- 210000000130 stem cell Anatomy 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 10
- 230000002188 osteogenic effect Effects 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 230000032677 cell aging Effects 0.000 description 8
- 230000032823 cell division Effects 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- JKYKXTRKURYNGW-UHFFFAOYSA-N 3,4-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=C(O)C(S(O)(=O)=O)=C2 JKYKXTRKURYNGW-UHFFFAOYSA-N 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 230000002596 correlated effect Effects 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000009168 stem cell therapy Methods 0.000 description 6
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 239000003636 conditioned culture medium Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000008672 reprogramming Effects 0.000 description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000049932 CD146 Antigen Human genes 0.000 description 3
- 108010025714 CD146 Antigen Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000003021 clonogenic effect Effects 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000023380 stress-induced premature senescence Effects 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102000010170 Death domains Human genes 0.000 description 2
- 108050001718 Death domains Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002293 adipogenic effect Effects 0.000 description 2
- 230000011759 adipose tissue development Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000010094 cellular senescence Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000002894 multi-fate stem cell Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- 108010081823 Myocardin Proteins 0.000 description 1
- 102100030217 Myocardin Human genes 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 101710178277 Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N beta-glycerol phosphate Natural products OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- GHRQXJHBXKYCLZ-UHFFFAOYSA-L beta-glycerolphosphate Chemical compound [Na+].[Na+].CC(CO)OOP([O-])([O-])=O GHRQXJHBXKYCLZ-UHFFFAOYSA-L 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011509 clonal analysis Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000034373 developmental growth involved in morphogenesis Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000026969 oncogene-induced senescence Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000008943 replicative senescence Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000002660 stem cell treatment Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Definitions
- the disclosure generally relates to a method of identifying aging
- MSCs Mesenchymal Stem Cells
- MSCs human mesenchymal stem cells
- stem cell research studies have been done to study the regenerative properties of human mesenchymal stem cells (MSCs) from bone marrow for the cells' potential therapeutic applications.
- MSCs are a promising source of adult stem cells for regenerative medicine, however many senescent cells are found in the heterogeneous ensemble of progenitors and lineage-committed cells that are associated with loss of proliferation potential and differentiation potential.
- Regenerative properties are highly variable among MSC subsets. Consequently, identification and isolation of progenitor subsets in heterogeneous MSC cultures are essential to the development of highly efficacious stem cell therapies.
- the elimination of senescent cells from heterogeneous MSC cultures may improve the treatment outcome of autologous MSC therapies by increasing both cell yield and enhancing the integrity of regenerated tissue.
- bio-markers such as antigens Neuron-Glial Antigen 2 (NG2) and Melanoma Cell Adhesion Molecule (CD 146) have been discovered.
- NG2 Neuron-Glial Antigen 2
- CD 146 Melanoma Cell Adhesion Molecule
- Flow cytometry is used in the sorting process. Cells with high surface expression of the antigen and cells with low surface expression of the antigen can be differentiated and separated by the flow cytometer. This method selects a proliferative phenotype from heterogeneous MSCs during ex vivo expansion.
- Another way to characterize cellular senescence is by using a proliferation dye.
- This dye can be used to measure the doubling time for MSCs of different sizes and granulation.
- a parent population is first dyed and then allowed to grow. As the cells divide, the dye is distributed approximately evenly amongst the daughter cells. Cells with a lower doubling time will therefore contain less dye after a given amount of time than cells with a high doubling time. This is because cells that divide rapidly will have distributed the dye amongst more daughters. If a fluorescent proliferation dye is chosen, FACS can be employed to separate subpopulations that either divide rapidly or slowly.
- a schematic representation of how proliferation dye works to identify rapidly and slowly dividing cells is presented in Figure 1.
- a current barrier to realizing the therapeutic potential of MSCs is the inability to identify different MSC populations in a heterogeneous culture.
- the heterogeneous cultures which include cells with lower proliferation and multipotent potential results in substantial variation and decreases the effectiveness of stem cell therapies with MSCs.
- this obstacle was addressed by previously unknown identification of two biomarkers, NG2 and CD 146, which select for highly proliferative multipotent MSCs.
- NG2 and CD 146 which select for highly proliferative multipotent MSCs.
- identifying and isolation of early aging MSCs is even more desirable to obtain MSCs with higher regenerative potential and better therapeutic efficacy.
- CD264 is widely expressed in tissues and therefore is not senescence-related.
- Degli-Esposti et al The Novel Receptor TRAIL-R4 Induces NF- ⁇ and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain, IMMUNITY (1997), Vol. 7, 813-820.
- CD264 is upregulated by oncogene -induced senescence, but "none was found upregulated in association to replicative senescence.”
- Collado et al Senescence in premalignant tumours, Nature (2005), Vol. 436, p. 642 (Supplementary Information).
- Zhu et al. further suggested that CD264 is upregulated by stress-induced premature senescence.
- Zhu et al Effects of estrogen on stress-induced premature senescence of vascular smooth muscle cells: A novel mechanism for the "time window theory" of menopausal hormone therapy, Atherosclerosis 215 (2011) 294- 300. .
- This invention provides a method of use of a cell-surface marker CD264 previously unknown for identifying and sorting early aging MSCs.
- the marker was previously not related to MSC differentiation and/or proliferation.
- the MSCs that positively express CD264 have morphologies consistent with known morphologies of aging MSCs.
- the resultant culture of isolated cells without expressing CD264 is enriched with MSCs of higher proliferation and differentiation potential with a broad range of regenerative properties of these stem cells, and therefore better efficacy in stem cell treatment schemes.
- This disclosure is for a method of characterization of MSC populations sorted by a unique cell death receptor, which is a marker of MSC early aging an/or senescence.
- a unique cell death receptor which is a marker of MSC early aging an/or senescence.
- Populations of cells with the death receptor can be evaluated for lack of regenerative/differentiation extent and colony-forming efficiency.
- Healthier population will have a low concentration of the death receptor on its surface, and will also display higher regenerative potential, higher differentiation trilineage potential and high colony- forming efficiency.
- early aging or senescent cells with a higher concentration of the death receptor underperform their healthy counterparts in both of these categories.
- the culture having aging MSCs may be rejuvenated when the aging MSCs constitute 50% of the entire population.
- the advantages of rejuvenating MSCs over reprogramming are threefold: (1) avoidance of genetic and epigenetic abnormalities from reprogramming; (2) prevention of teratoma formation from cells in a pluripotent state; and (3) efficiency of rejuvenating MSCs in terms of time, cell yield and cost. With these advantages, rejuvenation is a safer and more efficient alternative to restore the regenerative properties of MSCs than reprogramming.
- rejuvenation may be conducted in one of several ways: blocking certain signaling pathways that are related to cell aging, such as p38 MAPK signaling pathway; restoring telomerase activity; providing medium having composition similar to that in young stem cell cultures, among others.
- telomerase activity may be able to restore its regenerative and/or proliferative potential.
- CD264 was identified as a novel and unique cell-surface marker of pre- senescent MSCs at an early stage of aging.
- CD264 is a decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
- TRAIL tumor necrosis factor-related apoptosis-inducing ligand
- CD264 expression inhibits TRAIL-induced cell death and has never been associated with pre-senescent MSCs and has never been used to isolate aging MSCs.
- TRAIL-receptor 4 TRAIL-receptor 4
- DcR2 decoy receptor 2
- TRUNDD tumor necrosis factor receptor superfamily member lOd
- CD264 expression in MSCs is inversely correlated to the rate of cell division; only slowly dividing MSCs express CD264.
- CD264+ MSCs at early passage (passage 3) have greatly diminished colony-forming efficiency and differentiation potential relative to CD264- MSCs.
- the morphology of CD264+ MSCs is consistent with an aging cell: large size and granular cytoplasm.
- CD264+ MSCs at early passage express beta- galactosidase, they undergo cell division, albeit slowly, and thus are not yet senescent.
- the CD264 as a marker has a pattern of expression for certain MSCs after serial passages. A percentage of CD264+ MSCs in a heterogeneous population increases with passage as the overall culture ages.
- the expression of CD264 was compared with known intracellular proteins that regulate the cell cycle: pi 6, p21 and p53, and was found to correlate with p21.
- CD264 is the only surface marker discovered for early MSC aging and can be used on a method for sorting heterogeneous MCS populations. There are numerous uses of this method in addition to sorting MSCs. CD264 can be used to identify biological agents and culture conditions that could slow the rate of MSC aging and potentially reverse the aging process. In the clinic, the content of CD264+ cells in an MSC therapy could potentially predict its efficacy for a variety of therapeutic applications. Additionally, CD264 could be used to remove aging cells during the production of MSC therapies.
- this disclosure provides a method of identifying multipotent mesenchymal stem cells of high proliferation potential or trilineage potential, comprising the steps of a) collecting mesenchymal stem cells, b) measuring the expression of CD264, and c) removing the mesenchymal stem cells with positive expression of CD264.
- this disclosure provides a method of identifying multipotent mesenchymal stem cells of high proliferation potential, comprising the steps of: a) collecting mesenchymal stem cells, b) introducing fluorescent antibodies against CD264 to the collected mesenchymal stem cells, c) sorting the mesenchymal stem cells based on fluorescent characteristics thereof, and d) collecting the mesenchymal stem cells that are not bound by the fluorescent antibodies.
- this disclosure provides a composition comprising a population of mesenchymal stem cells having a colony forming efficiency of greater than 35% and trilineage potential, at least 50% of said mesenchymal stem cells having negative expression of CD264.
- this disclosure provides a cell-surface marker for identifying aging mesenchymal stem cells, wherein the cell-surface marker is CD264.
- this disclosure provides a cell-surface mark for identifying mesenchymal stem cells having low proliferation and trilineage potential, wherein the cell-surface marker is CD264.
- CD264 is used as a cell-surface marker for identifying aging MSCs, where the doubling time of CD264 + MSCs is at least twice as long as CD264 " MSCs.
- CD264 is used as a cell-surface marker for identifying aging MSCs, where the colony-forming efficiency of CD264 + MSCs is at least 3- fold less than CD264 " MSCs.
- CD264 is used as a cell-surface marker for identifying
- CD264 MSCs having low proliferation and trilineage potential, wherein the CD264 " MSCs produces at least 3-fold more mineralization than CD264 + MSCs.
- CD264 is used as a cell-surface marker for identifying
- CD264 MSCs having low proliferation and trilineage potential, wherein the CD264 " MSCs produces at least 3 -fold more lipids than CD264 + MSCs.
- TRUNDD TRAIL receptor with a truncated death domain acronym for
- TNFRSF10D Tumor necrosis factor receptor superfamily member 10d, acronym for CD264
- FIG. 1 is a schematic view illustrating how proliferation dye works to distinguish rapidly dividing MSCs from slowly dividing MSCs.
- FIG. 2 is a schematic view illustrating different strategies for sorting MSCs.
- FIG. 3 A-E Proliferation potential of MSCs sorted based on CellTrace Violet fluorescence.
- Parental MSCs P2 were labeled with CellTrace Violet and amplified for 4 days.
- Viable cells with the highest and lowest 10% of fluorescence intensity were sorted by FACS into slowly and rapidly dividing groups, respectively.
- Representative histograms from FACS analysis of 10,000 cells show (A) parental MSCs labeled with CellTrace Violet at 0 days (black) and 4 days (white), and (B) purity of sorted groups of rapidly (white) and slowly (black) dividing MSCs.
- C Growth curve of rapidly (circles) and slowly (triangles) dividing MSCs and parental MSCs (squares).
- FIG. 4A-F show representative images of stained cell culture in the surface marker negative and positive population.
- FIG. 5 Morphology and senescence of CD264 " and CD264 + MSCs.
- FIG. 6 is schematic views of the methodology employed to determine CFUs and osteogenic potential and quantification.
- FIG. 7. Proliferation and differentiation potential of CD264 " and CD264 +
- MSCs P3 MSCs were sorted based on CD264 expression as in Figure 16.
- A Growth curve of CD264 " (circles) and CD264 + (triangles) MSCs.
- B Doubling time of sorted MSCs calculated from exponential growth phase of growth curve.
- C Efficiency of sorted cells to form colonies when plated at clonogenic levels. Differentiation potential of sorted MSCs was evaluated after 21 days in (D,E,J) osteogenic medium by staining with Alizarin Red S to detect mineralization and (G,H,K) adipogenic medium by staining lipids with AdipoRedTM from Lonza. Adipo Negative control cultures (F,I) in growth medium. Scale bars: 100 mm.
- FIG. 8A-K shows phenotype comparison of CD264+ and CD264- MSCs during serial passage of parental MSC culture.
- FIG. 9A-C Co-expression of CD264 and p21 in serially passaged MSCs.
- MSCs were labeled with anti-CD264-PE, fixed, permeabilized, and co-labeled with anti-p21-AF488.
- A Representative bivariate histograms of co-labeled MSCs at select passages.
- B Corresponding percentages of MSCs that were CD264 " p21 " , CD264 + p21 " , CD264 " p21 + and CD264 + p21 + .
- CD264 as a cell-surface marker of human bone marrow
- CD264 is one of four cell- surface receptors (CD261-264) for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
- CD264 is a decoy receptor whose expression inhibits TRAIL- induced cell death.
- CD264 expression has been uniquely correlated to proliferation potential of MSCs among CD261-264.
- CD264+ MSCs at early passage have limited proliferation and differentiation potential relative to CD264- MSCs, showing that CD264 expression is indicative of an early stage of aging in a pre- senescent state.
- CD264+ MSCs at early passage have an enlarged, granular morphology and elevated expression of beta-galactosidase as compared with CD264- MSCs.
- the content of CD264+ cells in MSC cultures increase with serial passage. Further experiments are being conducted to determine the impact of the increasing CD264+ MSC content.
- CD264 is the only surface marker correlated with MSC early aging. More than 90% of the MSCs in this slowly dividing subset are CD264+ cells. In fact, relative to CD261 - CD263, CD264-positive cells were consistently the most prevalent among slowly dividing MSCs (data not shown). CD264 was selected for further analysis because of this strong inverse correlation between surface expression and the rate of cell division in early passage MSCs (data not shown).
- MSCs are known to be resistant to TRAIL-induced cell death (Szegezdi et al, 2009). Both CD264 " and CD264 + MSCs are equally refractory to this ligand (data not shown). As such, expression of this decoy receptor is not a prerequisite for TRAIL resistance in MSCs.
- CD264+ and CD264- MSCs lending support to the use of CD264 expression as the indicator of therapeutic efficacy.
- the CD264 expression was also correlated with p21 expression, which is upregulated at an early stage of cell aging.
- the CD264+ MSCs at early passage will be negative for pl6 expression, which is upregulated in senescence.
- the inventor's experiments revealed a clear linkage between CD264 and p21 that may be used to further improve the identification and enrichment procedure.
- the conditioned medium from osteogenic culture of CD264+ MSCs will inhibit the osteogenic potential of young CD264- MSCs.
- Conditioned medium from CD264- MSC culture will reverse MSC aging in part by promoting the osteogenic potential of CD264+ MSCs.
- conditioned medium from CD264- MSC culture may improve the efficacy of MSC therapies for bone regeneration (e.g., repair of broken bones, spinal fusion, and the treatment of osteoporosis, to name a few examples).
- CD264- conditioned medium can be used to remove inhibitory cells during the production of MSC bone therapies, or prolong the efficacy thereof.
- Heterogeneous MSCs from a single donor's bone marrow are sorted by flow cytometry based on the level of the expression of this surface receptor.
- the MSCs are separated into two populations: the population that has low expression of the surface marker CD264 and the population that has high expression of the surface marker.
- the sorting strategy is shown in Fig. 2.
- Each ball represents a cell. Hollow cells are rapidly dividing, and are therefore the most desired for stem cell therapies. Solid cells are close to senescent and are undesirable. Hatched cells are somewhere in the middle. The number each population is a relative indicator of fitness for use in therapies, with a 10 being the best possible combination. Stars indicate an antibody tag.
- MSC MSC-derived neurotrophic factor
- the characterization of MSC populations is based on their potency and proliferation.
- Three assays are used to characterize the two populations of MSCs separated by the surface receptor marker— Colony Forming Unit assay, beta- galactosidase staining, and trilineage potential assay.
- Colony forming unit assays study the efficiency with which MSCs form colonies and have proliferative potential. The results of the two populations are compared and used to determine whether a potential relationship between proliferative potential and the surface receptor expression can be demonstrated.
- Beta-galactosidase staining is a method to detect beta-galactosidase— enzyme that is associated with senescence. This assay is used to differentiate the senescent cells and all the other cells in the two populations. The results of this assay are used to investigate the percentage of senescent cells in each population.
- Trilineage potential assay quantifies the potency of single cell derived MSC colonies. Three different differentiation media are added to the colonies, and the assay quantifies trilineage potential to exhibit osteogenesis, adipogenesis, and chondrogenesis as a measure of potency. The results can be used to compare the potency of the two populations.
- Senescence-associated beta-galactosidase activity at pH 6.0 can be detected histochemically in subconfluent cultures, 4 days after inoculation, with the Senescence Beta-Galactosidase Staining kit (Cell Signaling Technology, Danvers, MA).
- Cell images of cultures stained for beta-galactosidase activity were captured with an Optronics DEI-750 digital camera (Goleta, CA) mounted onto an Olympus 1X50 microscope (Center Valley, PA).
- images of stained cells are analyzed with the background correction and optical density functions from Image-Pro Plus software (version 6.1, Media Cybernetics, Silver Spring, MD). Results are reported as a mean value from 30 randomly selected images per sample.
- MSCs were pre-labeled with CellTrace Violet proliferation dye and expanded prior to labeling with antibodies against the TRAIL receptors.
- the TRAIL receptor expression was examined as a function of the rate of cell division inasmuch as slower growth is a hallmark of cellular aging.
- Early-passage MSCs were selected for this initial experiment because inventors have demonstrated that these cultures contain cells with a broad spectrum of proliferation potential from rapid to slow cell division.
- MSCs were labeled with the CellTrace Violet proliferation dye and amplified for 4 days to detect cell division by dye dilution, as described in (Russell et al, 2013).
- the fluorescence intensity for the CellTrace dye is inversely correlated to the rate of cell division, as shown in FIG. 3.
- the fluorescence intensity of the CellTrace dye is inversely correlated to the rate of cell division.
- Viable cells with the highest and lowest 10% of fluorescence intensity for CellTrace Violet were FACS sorted into slowly and rapidly dividing cell groups, respectively (Figs. 3A and B).
- Figs. 3A and B At early passage, slowly dividing MSCs from the high CellTrace fluorescence group have doubling times that are 80% higher on average than rapidly dividing MSCs from the low CellTrace fluorescence group (Figs. 3C and D).
- Another measure of proliferation potential is the efficiency by which MSCs form colonies when plated at clonogenic levels.
- the colony-forming efficiency of slowing dividing MSCs from the high CellTrace fluorescence group is 20% on average the value of rapidly dividing MSCs from the low CellTrace fluorescence group (Fig. 3E), consistent with the relative doubling times for these two cell groups.
- Figures 4A-C show some representative images of stained cell culture, obtained from 7042R MSCs, in the surface marker negative population, while Figures 4D-F show some representative images of stained cell culture in the surface marker positive population.
- MCSs Primary MCSs were harvested from a 2 mL from the iliac crest of healthy adult volunteers. Cell culture reagents were obtained from Invitrogen (Carlsbad, CA) unless otherwise noted herein. MSCs were inoculated at 100 ⁇ 10 cells/cm 2 into 150 cm 2 T-flasks in Complete Culture Media with Antibiotics (CCMA) consisting of 500 mL MEM with L-gluatmine, 100 mL Fetal Bovine Serum (FBS; HyClone, Logan, UT; final concentration 16.5%), 6 mL L-glutamine (final concentration 2mM), and 6 mL penicillin/streptomycin (final concentration 100 units penicillin and 100 ⁇ g/mL streptomycin). MCSs were maintained at subconfluent in an incubator at 37°C and 5% C0 2 . All experiments described were conducted on cells at passages 3-5 unless otherwise noted.
- CCMA Complete Culture Media with Antibiotics
- Cell samples for immunolabeling were collected at subconfluent population densities.
- Cell suspensions of 2 x 10 6 cells/mL Phosphate-Buffered Saline (PBS) were immunolabled in aliquots of 100-500 for 30 minutes on ice in the dark with a fluorochrome-conjugated, anti-human monoclonal antibody against the death receptor.
- Labeled cells were washed three times with PBS and suspended at 5-6 x 10 6 cells/mL.
- Fig. 6 shows the methodology for determination of CFUs and osteogenic potential and quantification.
- the parent population is stained with a fluorescent primary antibody or alternatively with an unlabeled primary antibody followed by a secondary, anti-primary fluorescent antibody.
- the populations are sorted by FACS.
- (3 a) Cells positive for death receptor are cultured separately from the sorted population (negative). After two weeks, crystal violet staining is performed and the presence of CFUs is quantified by hand.
- (3b) Death receptor positive and death receptor negative cells are cultured in osteogenic differentiation media for three weeks concurrently with a death receptor negative group cultured in CCMA. After three weeks, all three groups are stained with Alizarin Red S, and a fluorescent plate reader is used to detect the presence of osteoblasts.
- MSCs were inoculated at 100 ⁇ 10 cells in a 10 cm cell culture plates and cultivated at 37°C and 5% C0 2 in CCMA for 14 days. Both MSCs positive and negative for death receptor were cultured. At the conclusion of this period, colonies were washed with water and stained with 3% crystal violet (Sigma- Aldrich, St. Louis, MO) in methanol for 20 minutes. Colonies were then washed in tap water until the background was clear. Colonies were counted by visual inspection. Individual, isolated cells were not considered to be colonies.
- DMEM low-glucose Dulbecco's Modified Eagle Medium
- FBS low-glucose Dulbecco's Modified Eagle Medium
- penicillin/streptomycin final concentration 100 units penicillin and 100 ⁇ g/mL streptomycin
- 100 nM Dexamethasone Sigma- Aldrich
- 10 mM ⁇ - glycerolphosphate Sigma-Aldrich
- 50 ⁇ L-Ascorbic acid 2-phosphate Sigma-Aldrich
- Alizarin Red S (Sigma-Aldrich) is used to detect calcium in the sample via a chelation process. The media was aspirated and each well was rinsed with PBS. 200 of 4% paraformaldehyde (Sigma-Aldrich) was added to each dish and incubated at room temperature for 20 minutes. The paraformaldehyde was removed and 200 ⁇ ⁇ of Alizarin Red S was added to each well with an incubation time of 20 minutes at room temperature. The well was washed with water until the background was clear, and a final rinse was conducted using PBS. Quantification is done using a spectrometer and normalizing to control wells which contained only CCMA. Figure 6 represents the overall methods for Determination of Colony Forming Efficiency (CFU) and Osteogenic Potential and Quantification.
- CFU Colony Forming Efficiency
- Heterogeneous MSCs were FACS (fluorescence activated cell sorting) sorted into CD264-negative and CD264-positive populations to evaluate the phenotype of each sort group (Figs. 5A and B).
- the sorted MSCs have 50% or more CD264- cells.
- the sorted MSCs have 75% or more CD264- cells.
- the sorted MSCs has 90% or more CD264- cells.
- Fig. 5B shows a purity of >99%> CD264- MSCs after sorting.
- the phase- contrast micrographs reveal that CD264 + MSCs were enlarged relative to CD264 " MSCs (Figs. 5C and D).
- CD264 + MSCs stained positive for senescence-associated ⁇ -galactosidase vs. ⁇ 3% for CD264 " MSCs (p ⁇ 0.01, Figs. 5C, D and G).
- the morphology and elevated ⁇ -galactosidase activity of CD264 + MSCs is consistent with an aging phenotype.
- CD264 + MSCs had a significantly lower proliferation potential.
- both sort groups were expanded ex vivo from an inoculum of 100 cells/cm 2 , the cell density for the CD264 " population was an order of magnitude higher after 8 days of amplification (Fig. 7A). This corresponds to a doubling time approaching once a day and every 3 days for CD264 " and CD264 + MSCs, respectively ( ⁇ 0.01, Fig. 7B).
- Fig. 7C is a bar-graph showing the average colony forming efficiencies for
- CD264 " cells displayed significantly greater colony forming potential than did CD264 + cells positive for death receptor (p ⁇ 0.01). Error bars represent the average ⁇ standard error of the mean. In fact, the CD264 + group formed clonogenic colonies ⁇ 4 times less efficiently (p ⁇ 0.01, Fig. 7C).
- the limited proliferation potential of CD264 + MSCs (Figs. 7A-C) coupled with their larger size and ⁇ - galactosidase staining (Fig. 5G) are classic features of cellular aging.
- Fig. 8 shows phenotypic comparison of CD264+ and CD264- MSCs during serial passage of parental MSC culture, originally obtained from donor 7042R. Representative histograms from flow cytometric analysis of 10,000 cells of parental MSCs labeled with isotype (A, C) and anti-CD264-PE (B, D) at passage 3 (A, B) and passage 7 (C, D). Percentage of parental MSCs positive for CD264 surface expression is shown in the upper right of the histograms B and D.
- CD264+ cells in MSC culture increases with serial passage: less that 10% at passage 3 to approximately 20% at passage 7 (p ⁇ 0.01, Figs. 8A- D).
- the morphology of CD264+ MSCs is consistent with that of an aging cell: large size and granular cytoplasm. This is evident in the phase- contrast micrographs (Figs. 8E-H) and in the scatter properties of the cells (Figs. 8I&J).
- the forward scatter, which is indicative of cell size, is 30%> - 40%> greater, on average, for CD264+ vs. CD264- MSC at passage 3 and 7 (p ⁇ 0.01, Fig. 81).
- CD264+ cells from the heterogeneous MSCs will provide an enriched, young population of MSCs.
- Other cell-cycle inhibitors are known to be upregulated in intermediate to late aging in MSCs, such as P53, pl6 and p21. Correlating CD264 expression with these cell-cycle inhibitors with CD264 will provide even more accurate prediction of MSC aging.
- a time-course study of the expression of CD264 in serially passaged MSCs was conducted and compared the temporal profile for CD264 expression to that of select cell-cycle inhibitors, p53, pl6 and p21.
- MSCs were strongly positive for p53 expression (data not shown): more than 80% of the cells were positive for this cell-cycle inhibitor throughout serial passage (data not shown).
- Expression of CD264 and p21 were upregulated concurrently first at Pl l and continued to increase at P14 (data not shown).
- the percentage of CD264 + MSCs doubled between P3 and PI 4, and there was a similar increase for p21 + cells (data not shown).
- Concurrent expression of CD264 and p21 indicates that CD264 is a cell-surface marker of an intermediate stage of replicative aging.
- MSCs have a primarily CD264 " p21 " phenotype at early passage, and the fraction of CD264 ⁇ p2rcells decreased during serial passage as they progressed to one of two transitional states: CD264 + p21 " or CD264 " p21 + (FIG. 9A-B). While there was a pool of CD264 " p21 " MSCs in culture, the fraction of CD264 + p21 " and CD264 " p21 + cells were fairly independent of passage number (FIG. 9B), and CD264 + p21 " and CD264 " p21 + cells converted to a CD264 + p21 + phenotype, which accumulated at Pl l and P14 (FIG. 9A-B).
- the schematic in Figure 9C depicts the progression of MSCs from a CD264 " p21 " phenotype through transitional states to a CD264 + p21 + phenotype.
- the accumulation of CD264 + p21 + MSCs during serial passage illustrates linkage between CD264 and p21. Therefore, in addition to CD264, co-expression of CD264 and p21 may be used as indicator of aging MSC populations.
- Immense complexity is found in the heterogeneity of mesenchymal stem cell populations.
- CD264- cell cultures and conditioned media can be used to enhance therapies using MSCs to exclude cells with high expression of the cell death receptor.
- CD264 expression is present in early passage MSC populations, as early as passage 3 and accumulate over time. Avoiding the use of MSCs with CD264+ will enhance the effectiveness of stem cell therapies by providing more proliferation.
- Heterogeneity is a major stumbling block to stem cell therapies.
- This invention presents sorting methods that will enhance the use of MSCs by providing a more robust population of MSCs possible from a donor.
- CD264 could be used to monitor cell aging during ex vivo expansion to generate sufficient amount of MSCs for therapeutic application. This marker may provide a means to remove aging cells during the production of MSC therapies.
- CD264 is the only surface marker discovered for early MSC aging and thus can be used on a method for sorting heterogeneous MCS populations. There are numerous uses of this method in addition to sorting MSCs. CD264 can be used to identify biological agents and culture conditions that could slow the rate of MSC aging and potentially reverse the aging process.
- This disclosure can be employed, for instance, to monitor MSC preparations in the clinic for consistent content of multipotent cells and to determine the variability in heterogeneity among different donors, with age and under different culture conditions.
- the content of CD264+ cells in an MSC therapy could potentially predict its efficacy for a variety of therapeutic applications. Additionally, CD264 could be used to remove aging cells during the production of MSC therapies.
- the method of this disclosure can be used to identify other factors associated with MSC multipotency. Using this invention makes it possible to exploit differential growth kinetics to enrich multipotent cells in a heterogeneous MSC preparation during ex vivo amplification for clinical use by using the marker CD264. The ease of identification of MSCs with multipotency and efficient colony formation, and further culturing of the isolated MSCs with negative expression of CD264 can provide a source of MSCs for improved therapy and research. [0092] Each of the following references is incorporated herein in its entirety for all purposes:
- US20140065112 Compositions and methods for mesenchymal/stromal stem cell rejuvenation and tissue repair by enhanced co-expression of telomerase and myocardin, published on March 6, 2014.
- US20140322811 Medium composition for rejuvenating stem cells, published on October 30, 2014.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461978708P | 2014-04-11 | 2014-04-11 | |
PCT/US2015/025411 WO2015157694A1 (en) | 2014-04-11 | 2015-04-10 | Cell-surface marker of early msc aging |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3129469A1 true EP3129469A1 (en) | 2017-02-15 |
EP3129469A4 EP3129469A4 (en) | 2017-11-01 |
EP3129469B1 EP3129469B1 (en) | 2022-07-27 |
Family
ID=54288456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15776062.0A Active EP3129469B1 (en) | 2014-04-11 | 2015-04-10 | Cell-surface marker of early msc aging |
Country Status (5)
Country | Link |
---|---|
US (1) | US10458985B2 (en) |
EP (1) | EP3129469B1 (en) |
AU (1) | AU2015243236B2 (en) |
CA (1) | CA2944703C (en) |
WO (1) | WO2015157694A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015243236B2 (en) | 2014-04-11 | 2020-12-03 | The Administrators Of The Tulane Educational Fund | Cell-surface marker of early MSC aging |
WO2020191115A1 (en) * | 2019-03-19 | 2020-09-24 | The Administrators Of The Tulane Educational Fund | Method of improving the in vivo survival of mesenchymal stem cells |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003901668A0 (en) * | 2003-03-28 | 2003-05-01 | Medvet Science Pty. Ltd. | Non-haemopoietic precursor cells |
CN103261407B (en) * | 2010-12-22 | 2016-03-02 | 杜兰教育基金委员会 | For identifying and cultivate the method for the multipotency mescenchymal stem cell with hyperproliferation potential |
US20120276064A1 (en) | 2011-04-05 | 2012-11-01 | Blau Helen M | Methods and compositions for rejuvenation and expansion of stem cells |
EP2773746A4 (en) | 2011-11-01 | 2015-08-05 | Neostem Inc | Adult mesenchymal stem cell (msc) compositions and methods for preparing the same |
EP2811015B1 (en) | 2011-12-01 | 2020-09-02 | R Bio Co., Ltd. | Culture-medium composition for rejuvenating stem cells |
CN104204192A (en) * | 2012-02-13 | 2014-12-10 | 加米达细胞有限公司 | Mesenchymal stem cells conditioned medium and methods of generating and using the same |
US20140065112A1 (en) | 2012-08-24 | 2014-03-06 | Texas Heart Institute | Compositions and methods for mesenchymal/stromal stem cell rejuvenation and tissue repair by enhanced co-expression of telomerase and myocardin |
AU2015243236B2 (en) | 2014-04-11 | 2020-12-03 | The Administrators Of The Tulane Educational Fund | Cell-surface marker of early MSC aging |
-
2015
- 2015-04-10 AU AU2015243236A patent/AU2015243236B2/en active Active
- 2015-04-10 WO PCT/US2015/025411 patent/WO2015157694A1/en active Application Filing
- 2015-04-10 CA CA2944703A patent/CA2944703C/en active Active
- 2015-04-10 US US15/302,462 patent/US10458985B2/en active Active
- 2015-04-10 EP EP15776062.0A patent/EP3129469B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2015243236B2 (en) | 2020-12-03 |
CA2944703A1 (en) | 2015-10-15 |
US10458985B2 (en) | 2019-10-29 |
EP3129469A4 (en) | 2017-11-01 |
EP3129469B1 (en) | 2022-07-27 |
CA2944703C (en) | 2023-09-19 |
US20170016898A1 (en) | 2017-01-19 |
AU2015243236A1 (en) | 2016-10-13 |
WO2015157694A1 (en) | 2015-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sakai et al. | Successful fishing for nucleus pulposus progenitor cells of the intervertebral disc across species | |
US10935542B2 (en) | Method for identification and culture of multipotent mesenchymal stem cells with high proliferation potential | |
WO2011034106A1 (en) | Method for isolation of dermal stem cell | |
JP2009060840A (en) | Method for concentrating human mesenchymal stem cell | |
Chan et al. | Multiparameter flow cytometry for the characterisation of extracellular markers on human mesenchymal stem cells | |
CN104471073A (en) | Cell-surface signatures for isolating neurons from cell cultures derived from pluripotent stem cells | |
JP2008220334A (en) | Use of cd106 as differentiation potency marker of mesenchymal stem cell | |
AU2015243236B2 (en) | Cell-surface marker of early MSC aging | |
Kos et al. | Flow cytometry-based isolation of tumor-associated regulatory T cells and assessment of their suppressive potential | |
Heazlewood et al. | The prospective isolation of viable, high ploidy megakaryocytes from adult murine bone marrow by fluorescence activated cell sorting | |
WO2021144995A1 (en) | High-purity mesenchymal stem cells | |
CA2682317C (en) | Enrichment of tissue-derived adult stem cells based on retained extracellular matrix material | |
Maric et al. | Fluorescence‐Based Sorting of Neural Stem Cells and Progenitors | |
JP6606413B2 (en) | Method for detecting and separating dermal stem cells | |
JP2017108674A (en) | Method of detecting and separating fat stem cell | |
CN108753685B (en) | Separation, screening, culture and function identification method of human aortic vessel wall stem cells expressing c-Kit | |
Ganguly | Bone-resident mesenchymal stromal cells in healthy ageing and osteoarthritis: enumeration and gene expression analysis in uncultured cells | |
Madhavan | Does the presence of disseminated tumour cells in bone marrow or circulating tumour cells predict early tumour recurrence in patients with oesophagogastric cancer? | |
McEnerney | Isolation and expansion of human skeletal stem cells | |
Sheard | Screening and improving the safe provision of mesenchymal stem cells in regenerative medicine: an in vitro study | |
CN113136411A (en) | Evaluation method using human stem cells, drug evaluation method, and detection kit | |
Hewitt | Alexander KC Chan, Thomas RJ Heathman, Karen Coopman & | |
Sudarsanam et al. | IMMUNOPHENOTYPIC CHARACTERIZATION O THEIR SIDE PO | |
JP2008092891A (en) | Method for separating retinal stem cell and retinal stem cell |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20161102 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20171004 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 1/04 20060101ALI20170927BHEP Ipc: C07K 14/47 20060101ALI20170927BHEP Ipc: G01N 15/14 20060101ALI20170927BHEP Ipc: C12Q 1/02 20060101ALI20170927BHEP Ipc: C07K 14/705 20060101ALI20170927BHEP Ipc: G01N 33/569 20060101ALI20170927BHEP Ipc: C12N 5/0775 20100101AFI20170927BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20190228 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20220221 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602015080049 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1507094 Country of ref document: AT Kind code of ref document: T Effective date: 20220815 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20220727 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221128 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221027 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1507094 Country of ref document: AT Kind code of ref document: T Effective date: 20220727 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221127 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221028 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602015080049 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 |
|
26N | No opposition filed |
Effective date: 20230502 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20230620 Year of fee payment: 9 Ref country code: CH Payment date: 20230701 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230410 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20230430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230410 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230410 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240229 Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240308 Year of fee payment: 10 |